Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-05-09
2006-05-09
Romeo, David S. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S486000, C424S488000, C514S801000, C530S350000, C530S356000
Reexamination Certificate
active
07041641
ABSTRACT:
Disclosed herein are improved osteogenic devices and methods of use thereof for repair of bone and cartilage defects. The devices and methods promote accelerated formation of repair tissue with enhanced stability using less osteogenic protein than devices in the art. Defects susceptible to repair with the instant invention include, but are not limited to: critical size defects, non-critical size defects, non-union fractures, fractures, osteochondral defects, subchondral defects, and defects resulting from degenerative diseases such as osteochondritis dessicans.
REFERENCES:
patent: 4353982 (1982-10-01), Gomez et al.
patent: 4968590 (1990-11-01), Kuberasampath et al.
patent: 4975526 (1990-12-01), Kuberasampath et al.
patent: 5011691 (1991-04-01), Oppermann et al.
patent: 5013649 (1991-05-01), Wang et al.
patent: 5073373 (1991-12-01), O'Leary et al.
patent: 5171574 (1992-12-01), Kuberasampath et al.
patent: 5266683 (1993-11-01), Oppermann et al.
patent: 5354557 (1994-10-01), Oppermann et al.
patent: 5366964 (1994-11-01), Lindstrom et al.
patent: 5385887 (1995-01-01), Yim et al.
patent: 5422340 (1995-06-01), Ammann et al.
patent: 5457093 (1995-10-01), Cini et al.
patent: 5468845 (1995-11-01), Oppermann et al.
patent: 5520923 (1996-05-01), Tjia et al.
patent: 5597897 (1997-01-01), Ron et al.
patent: 5645591 (1997-07-01), Kuberasampath et al.
patent: 5674292 (1997-10-01), Tucker
patent: 5674844 (1997-10-01), Kuberasampath et al.
patent: 6232458 (2001-05-01), Weiss et al.
patent: 0 723 013 (1996-07-01), None
patent: WO 90/11366 (1990-10-01), None
patent: WO 91/18098 (1991-11-01), None
patent: WO 91/18558 (1991-12-01), None
patent: 94 15653 (1994-07-01), None
patent: 94 20133 (1994-09-01), None
patent: WO 95/16035 (1995-06-01), None
patent: WO 95/24210 (1995-09-01), None
patent: WO 95/25546 (1995-09-01), None
patent: 96 09078 (1996-03-01), None
patent: WO 96/39169 (1996-12-01), None
patent: WO 96/39170 (1996-12-01), None
patent: WO 96/40297 (1996-12-01), None
Ogawa et al. Bovine bone activin enhances bone morphogenetic protein-induced ectopic bone formation. J Biol Chem, (Jul. 15, 1992) 267 (20) 14233-7.
Bowie et al. Deciphering the message in protein sequences: tolerance to amino acid substitutions. Science, (Mar. 16, 1990) 247 (4948) 1306-10, Aug. 1990.
Sato et al. Bone morphogenesis of rabbit bone morphogenetic protein-bound hydroxyapatite-fibrin composite. Clin Orthop Feb. 1991;(263):254-62.
Doll et al. Journal of Periodontology, (Dec. 1990) 61 (12) 745-50.
Alberts et al., Molecular Biology of the Cell, 1983, Garland Publishing, Inc., New York, NY, pp. 692, 693, 705.
Reddi A. H. Journal of Cellular Biochemistry (Oct. 1994) 56 (2) 192-5.
FMC Corp., Technical Bulletin RC-16, 1986, pp. 1-8.
Handbook of Pharmaceutical Excipients, 2nd ed., A. Wade and P. J. Weller (eds), American Pharmaceutical Association, Washington, DC, Jan., 1994, p. xiii.
Bulletin VC-453C, “Rheology of AQUALON® Water-Soluble Polymers in Solution,” Hercules Incorporated, Aqualon Division, Hercules Plaza, 1313 North Market Street, Wilmington, DE 19894-0001, 2001.
Arnaud et al. Potentiation of transforming growth factor (TGF-beta 1) by natural coral and fibrin in a rabbit cranioplasty model. Calcif Tissue Int. Jun. 1994;54(6):493-8.
Turco, S.J. “Intravenous Admixtures”, Chapter 85, in, Remington's Pharmaceutical Sciences, 18th edition (Jun. 1990), Mack Pub. Co., Easton, Pennsylvania, p. 1570
Beck et al., “TGF-β1Induces Bone Closure of Skull Defects,”Journal of Bone and Mineral Research, 6(11):1257-1265 (1991).
Beck et al., “The Single Application of TGF-β1Induces Closure of Skull Defects,”Journal of Bone and Mineral Research, 6(1):155 (1991).
Kenley et al., “Osseous Regeneration in the Rat Calvarium Using Novel Delivery Systems for Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2),”Journal of Biomedical Materials Research, 28:1139-1147 (1994).
Cook et al., “Recombinant Human Bone Morphogenetic Protein-7 Induces Healing in a Canine Long-Bone Segmental Defect Model,”Clinical Orthopaedics and Related Research, 301:302-312 (Apr. 1994).
Cook et al., “The Effect of Recombinant Human Ostogenic protein-1 on Healing of Large Segmental Bone Defects,”The Journal of Bone and Joint Surgery, 76-A(6):827-838 (Jun. 1994).
Schmitz and Hollinger, “The Critical Size Defect as an Experimental Model for Craniomandibulofacial Nonunions,”Clinical Orthopaedics and Related Research, 205:299-308(1986).
Sampath and Reddi, “Homology of bone-inductive proteins from human, monkey, bovine, and rat extracellular matrix,”Proc. Natl. Acad. Sci. USA, 80:6591-6595 (Nov. 1983).
Vukicevic et al., “Extracellular Matrix and Bone Morphogenetic Proteins in Cartilage and Bone Development and Repair,”Advances in Molecular and Cell Biology, 6:207-224 (1993).
Dayhoff et al.,“A Model of Evolutionary Change in Proteins,” in 5Atlas of Protein Sequence and StructureCh. 22, Supp. 3, pp. 345-352. (1978).
Snopek, “Contrast Media” inFundamentals of Special Radiographic Procedures, (Pennsylvania: Harcourt), pp. 66-76 (1992).
Carroll, “Patient Status and Contrast Agents” inFuchs's Radiographic Exposure, Proceesing and Quality Control, (Charles C. Thomas Publisher: Illinois), pp. 151-154 (1993).
Ehrlich and McCloskey, “Contrast Media and Special Imaging Techniques” inPatient Care in Radiography, (St. Louis: Mosby), pp. 211-254 (1993).
LeGeros, “Calcium Phosphate Materials in Restorative Dentistry: A Review,”Advances in Dental Research, 2(1):164-180, (Aug., 1988).
Shapiro, “Cell Origin and Differentiation in the Repair of Full-Thickness Defects of Articular Cartilage,”The Journal of Bone and Joint Surgery 75-A(4):532-553, Apr., 1993).
Cao et al.,“Water Vapour-Treated Hydroxyapatite Coatings After Plasma Spraying and Their Characteristics,”Biomaterials, 17(4):419-424, (1996).
Piatelli et al., “Clinical and Histologic Aspects of Biphasic Calcium Phosphate Ceramic (BCP) Used in Connection With Implant Placement,”Biomaterials, 17(18):1767-1770, (1996).
Johnson et al., “Porous Ceramics as Bone Graft Substitutes in Long Bone Defects: A Biomechanical, Histological, and Radiographic Analysis,”Journal of Orthopaedic Research, 14:351-369, (1996).
LeGeros and Daculsi, “In VivoTransformation of Bisphasic Calcium Phosphate Ceramics: Ultrastructural and Physicochemical Characterizations,” in IICRC Handbook of Bioactive Ceramics(CRC Press), pp. 17-28 (1990).
Rueger David C.
Tucker Marjorie M.
Fish & Neave IP Group Ropes & Gray LLP
Haley Jr. James F.
Mangasarian Karen
Romeo David S.
Stryker Corporation
LandOfFree
Osteogenic devices and methods of use thereof for repair of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Osteogenic devices and methods of use thereof for repair of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Osteogenic devices and methods of use thereof for repair of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3555911